ClinicalTrials.gg
Sign In
RecruitingNCT07166172Updated Apr 23, 2026

Prospective Registry for Long-term Outcomes Following FETO in Severe Left and Right CDH

An interventional study of Fetal Treatment Arm (FETO Group) in Congenital Diaphragmatic Hernia, Congenital Abnormalities and Neonatal Diseases and Abnormalities, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This registry study aims to confirm that FETO increases neonatal survival to discharge and reduces long-term morbidity in fetuses with isolated left CDH and o/e LHR \< 30%, or isolated right CDH and o/e LHR ≤ 45%, compared to those receiving standard care. This prospective registry plans to enroll 80 pregnant women (40 treatment/40 control) with fetuses diagnosed with isolated CDH, and the children will be followed for up to 24 months.

Read the detailed description

The purpose of this study is to evaluate successful placement and removal of Fetoscopic Endoluminal Tracheal Occlusion (FETO) device in cases of intrathoracic liver herniation with isolated left congenital diaphragmatic hernia (LCDH) with Observed/Expected (O/E) Lung to Head Circumference Ratio (LHR) \< 30% or isolated right congenital diaphragmatic hernia (RCDH) with O/E LHR ≤ 45%,to compare survival to discharge from the neonatal intensive care units (NICU), between fetuses with intrathoracic liver herniation and isolated LCDH with O/E LHR \< 30% that receive FETO procedure performed at 27 weeks + 0 days to 29weeks + 6 days of gestation to those with intrathoracic liver herniation, isolated LCDH and o/e LRH \< 30% that undergo expectant management, to compare the neonatal survival rate to discharge from the neonatal intensive care units (NICU), between fetuses with intrathoracic liver herniation, isolated RCHD with o/e LHR ≤ 45% that undergo FETO procedure performed at 27 weeks + 0 days to 29 weeks + 6 days gestation to those with intrathoracic liver herniation, isolated RCHD and o/e LHR ≤ 45% that elect to proceed with expectant management, to evaluate the frequency of maternal and fetal complications associated with FETO procedure, to evaluate whether the FETO procedure is associated with reduced long-term mortality and morbidities in isolated LCDH survivors with o/e LHR \<30% when compared to isolated LCDH with o/e LRH \<30% that undergo expectant management where all fetuses were found to have intrathoracic liver herniation and to evaluate whether the FETO procedure is associated with reduced long-term mortality and morbidities in isolated RCDH survivors with o/e LHR ≤ 45% when compared to isolated RCHD with LHR ≤ 45% that undergo expectant management where all fetuses were found to have intrathoracic liver herniation.

02

Conditions studied

  • Congenital Diaphragmatic Hernia
  • Congenital Abnormalities
  • Neonatal Diseases and Abnormalities
  • Hernia, DIaphragmatic, Congenital
  • Internal Hernia
  • Hernia
  • Pathological Conditions, Anatomical
  • Pathological Conditions, Signs and Symptoms

Keywords

  • Fetoscopic Endoluminal Tracheal Occlusion
03

In context

Hernias, Diaphragmatic, Congenital

86 studies on the registry are indexed under Hernias, Diaphragmatic, Congenital; 39 are open to participants now.

This study's planned enrollment of 80 is above the median of 30 across 62 interventional studies indexed under Hernias, Diaphragmatic, Congenital.

Browse Hernias, Diaphragmatic, Congenital studies →

Lead sponsor

Johns Hopkins University is the lead sponsor of 1,815 studies on the registry; 315 are open to participants now.

Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.

Browse Johns Hopkins University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women age 18 years and older
  • Singleton pregnancy
  • Normal Karyotype, chromosomal microanalysis (CMA) with non-pathologic variants, whole exome sequencing (WES) or whole genome sequencing (WGS). Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is > 26 weeks gestation.
  • Gestational age at enrollment is prior to 29 weeks + 6 days gestation.

  • Intrathoracic liver herniation:

    • Isolated left CDH with o/e LHR \< 30% at enrollment (18wks + 0 days to 29wks + 5 days gestation).
    • Isolated right CDH with o/e LHR ≤ 45% at enrollment (18wks + 0 days to 29wks + 5 days gestation).
  • Cervical length by transvaginal ultrasound ≥ 20 mm within 24 hours prior to FETO procedure.
  • Patient meets psychosocial criteria.
  • understood.

Exclusion criteria

Exclusion Criteria:

  • Patient \< 18 years of age
  • Multi-fetal pregnancy
  • History of natural rubber latex allergy
  • Preterm labor, cervix shortened (\<20 mm at enrollment or within 24 hours of FETO balloon insertion procedure) or uterine anomaly strongly predisposing to preterm labor, placenta previa.

  • Psychosocial ineligibility, precluding consent:

    1. Inability to reside within 30 minutes of Johns Hopkins Hospital Center for Fetal Therapy.
    2. The patient does not have a support person (e.g., spouse, partner, mother) available to stay with the patient for the duration of the pregnancy at Johns Hopkins Hospital Center for Fetal Therapy.
  • Bilateral CDH, isolated left sided CDH with O/E LHR ≥ 30% (18wks + 0 days to 29wks + 5 days gestation), isolated right sided CDH with O/E LHR > 45% (18wks + 0 days to 29wks + 5 days gestation), as determined by ultrasound.
  • No liver herniation into thoracic cavity.
  • Additional fetal anomaly and chromosomal abnormalities by ultrasound, MRI, or echocardiogram at the fetal treatment center. Exclude chromosomal abnormalities, associated anomalies recognized to alter survival prognosis (i.e., CDH and congenital heart disease) or presence of an underlying genetic syndrome (i.e., Fryns).
  • Maternal to fetoscopic surgery or severe maternal medical condition in pregnancy.
  • History of incompetent cervix with or without cerclage.
  • Placental abnormalities (previa, abruption, accreta) known at time of enrollment
  • Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy.
  • Maternal , Hepatitis-B, Hepatitis-C status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis status is unknown, the patient must be tested and found to have negative results before enrollment.
  • Uterine anomalies such as large or multiple fibroids or Mullerian duct abnormality.
  • There is no safe or technically feasible fetoscopic approach to balloon placement.
  • Participation in another intervention study that influences maternal and fetal morbidity and mortality. or participation in this trial in a previous pregnancy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Fetal Treatment Arm (FETO Group)

    Device: Fetal Treatment Arm (FETO Group)

  • No intervention
    Expectant Management Arm (Control Group)

    Standard of care treatment for babies with congenital diaphragmatic hernia.

Interventions

  • DeviceFetal Treatment Arm (FETO Group)

    Participants will undergo FETO surgery between 27 weeks + 0 days to 29 weeks + 6 days gestation. The FETO intervention involves two procedures: (1) inserting a balloon into the fetal trachea, and (2) removing the balloon before delivery. After the first FETO procedure, participants will be monitored weekly by ultrasound. Removal of the balloon will be performed at 34 weeks + 0 days to 34 weeks + 6 days gestation. Planned delivery will occur after 37 weeks. The follow-up phase will be conducted from birth to 24 months of age.

    Also known as: Fetal Endoluminal Tracheal Occlusion (FETO)

06

What researchers measure

Primary outcomes

  1. Number of successful placement of FETO device

    Time frame: 10-60 minutes after surgery begins

  2. Number of successful removal of FETO device

    Time frame: Immediately after the procedure (about 1 hour after start of surgery)

  3. Number of FETO procedure complications

    Complications include: Failure FETO insertion procedure, FETO device dislodgement potentially requiring a second FETO insertion, Fetal intraoperative injury, Procedural hemorrhage, Bleeding from insertion site or Abruptions, Post-procedural hemorrhage PPROM, Preterm delivery, Chorioamnion separation, Chorioamnionitis, Polyhydramnios, Oligohydramnios, Emergent removal due to obstetrical complication, Failed percutaneous or fetoscopic removal requiring cesarean section or exit procedure for removal, Neonatal death due to asphyxia if delivery before FETO removal, and Non-reassuring fetal heart rate monitoring.

    Time frame: End of study (24 months)

  4. Number of neonates that survived

    Neonatal survival to discharge

    Time frame: From delivery to hospital discharge

Secondary outcomes

  1. Number of infants that survived

    Time frame: 6 months

  2. Number of infants that survived

    Time frame: 12 months

  3. Number of infants that survived

    Time frame: 18 months

  4. Number of infants that survived

    Time frame: 24 months

  5. Number of infants that show presence of pulmonary hypertension

    Time frame: 6 months

  6. Number of infants that show presence of pulmonary hypertension

    Time frame: 12 months

  7. Number of infants that show presence of pulmonary hypertension

    Time frame: 18 months

  8. Number of infants that show presence of pulmonary hypertension

    Time frame: 24 months

  9. Number of infants that show need for supplemental oxygen

    Time frame: 6 months

  10. Number of infants that show need for supplemental oxygen

    Time frame: 12 months

  11. Number of infants that show need for supplemental oxygen

    Time frame: 18 months

  12. Number of infants that show need for supplemental oxygen

    Time frame: 24 months

  13. Number of infants that show periventricular leukomalacia

    Time frame: At less than 2 months postnatally

  14. Number of Infants that develop sepsis

    Time frame: 6 months

  15. Number of Infants that develop sepsis

    Time frame: 12 months

  16. Number of Infants that develop sepsis

    Time frame: 18 months

  17. Number of Infants that develop sepsis

    Time frame: 24 months

  18. Number of infants that develop Intraventricular hemorrhage (grade 0-III)

    Time frame: 6 months

  19. Number of infants that develop Intraventricular hemorrhage (grade 0-III)

    Time frame: 12 months

  20. Number of infants that develop Intraventricular hemorrhage (grade 0-III)

    Time frame: 18 months

  21. Number of infants that develop Intraventricular hemorrhage (grade 0-III)

    Time frame: 24 months

  22. Number of infants that develop retinopathy of prematurity (grade 3 or higher)

    Time frame: 6 months

  23. Number of infants that develop retinopathy of prematurity (grade 3 or higher)

    Time frame: 12 months

  24. Number of infants that develop retinopathy of prematurity (grade 3 or higher)

    Time frame: 18 months

  25. Number of infants that develop retinopathy of prematurity (grade 3 or higher)

    Time frame: 24 months

  26. Number of infants that develop gastro-esophageal reflux

    Time frame: 6 months

  27. Number of infants that develop gastro-esophageal reflux

    Time frame: 12 months

  28. Number of infants that develop gastro-esophageal reflux

    Time frame: 18 months

  29. Number of infants that develop gastro-esophageal reflux

    Time frame: 24 months

  30. Number of infant hospital readmissions

    Time frame: End of study (24 months)

  31. Cause of infant hospital readmissions

    Time frame: End of study (24 months)

  32. Number of infants that show childhood growth failure

    Time frame: 6 months

  33. Number of infants that show childhood growth failure

    Time frame: 12 months

  34. Number of infants that show childhood growth failure

    Time frame: 18 months

  35. Number of infants that show childhood growth failure

    Time frame: 24 months

  36. Number of infants that show recurrence of CDH repair

    Time frame: 6 months

  37. Number of infants that show recurrence of CDH repair

    Time frame: 12 months

  38. Number of infants that show recurrence of CDH repair

    Time frame: 18 months

  39. Number of infants that show recurrence of CDH repair

    Time frame: 24 months

  40. Number of infants that develop bowel obstruction

    Time frame: 6 months

  41. Number of infants that develop bowel obstruction

    Time frame: 12 months

  42. Number of infants that develop bowel obstruction

    Time frame: 18 months

  43. Number of infants that develop bowel obstruction

    Time frame: 24 months

  44. Number of infants that show neurodevelopmental delay as assessed by the Bayley Scales of Infant and Toddler Development-III(BSID)

    Three domains will be measured as follows: Cognitive Scale, Language Scale (Receptive and Expressive) and Motor Scale (Fine and Gross Motor Skills). Scores are derived by converting raw scores from completed tasks into scale scores and composite scores. These scores are then utilized to assess the child's performance in relation to norms established based on typically developing children of the same age Mean score of 100 (SD=15) at the 50th percentile signifies mid-average functioning. Scores below 85 (1 SD below the mean), at the 16th percentile, indicate mild impairment of being 'at risk' of developmental delay. Score below 70 (2 SD below the mean), at the second percentile, indicate moderate to severe impairment. In general, scores falling in the lowest 10th percentile indicate developmental delay

    Time frame: 24 months

  45. Number of infants that develop bronchopulmonary dysplasia

    Time frame: 6 months

  46. Number of infants that develop bronchopulmonary dysplasia

    Time frame: 12 months

  47. Number of infants that develop bronchopulmonary dysplasia

    Time frame: 18 months

  48. Number of infants that develop bronchopulmonary dysplasia

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2029, 53 months after the start.

Of 40 interventional studies with no phase under Hernias, Diaphragmatic, Congenital, half reached primary completion within 108 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 133. This study's planned 53 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2025
First posted
Sep 10, 2025
StartActual
Jun 23, 2025
Primary completionEst.
Dec 1, 2029
CompletionEst.
Dec 1, 2031
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07166172
Lead sponsor
Johns Hopkins University
Collaborators
KARL STORZ Endoscopy-America, Inc.
Responsible party
Sponsor
First posted
Sep 10, 2025
Start date
Jun 23, 2025
Primary completion
Dec 1, 2029 (estimated)
Completion
Dec 1, 2031 (estimated)
Last update
Apr 23, 2026

Study contacts

Ahmet Baschat, MD
Contact
abascha1@jhmi.edu
410-502-6561
Ahmet Baschat, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hernias, Diaphragmatic, Congenital →

Other studies from this sponsor

Johns Hopkins University →

Start the discussion